Diabetic Gastroparesis Clinical Trial
— TEAOfficial title:
Transcutaneous Electroacupuncture for Gastroparesis
Verified date | April 2017 |
Source | Transtimulation Research, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Gastroparesis is a common disease defined as delayed emptying of the stomach. It is present
in at least 20% of about 150 million patients with diabetes worldwide and in more than 20%
of patients with functional dyspepsia that affects about 10%-25% of the general population.
Gastroparesis is a refractory disease with a lack of therapeutic options. Common symptoms of
gastroparesis include nausea, vomiting, early satiety and abdominal bloating.
Electroacupuncture (EA) is a combined procedure with acupuncture and electrical current
stimulation instead of manual manipulations of the needles. Recent studies in our lab with
EA or transcutaneous EA (TEA) have suggested a therapeutic role of EA or TEA for gastric
motility disorders. Improvement has been observed with EA or TEA in gastric emptying as well
as dyspeptic symptoms. In this project, a micro-stimulator is designed and developed for the
TEA therapy. The micro-stimulator is small enough so that it can be attached to the skin
next to the stimulation electrodes and therefore the patient can resume normal daily
activity while being treated by TEA. This is not only attractive but also more effective
since TEA can be performed more often and for longer durations.
This exploratory project is designed to study the feasibility, efficacy and certain
mechanisms of the proposed method of "wireless" TEA in patients with gastroparesis. Firstly
the feasibility of the chronic use the proposed micro-stimulator will be studied. Secondly,
the efficacy of the TEA in improving delayed gastric emptying and symptoms of gastroparesis
will be investigated in a double-blinded crossover design in patients with diabetic or
idiopathic gastroparesis. Thirdly, possible mechanisms involving pathogeneses of
gastroparesis with TEA will be investigated.
Status | Completed |
Enrollment | 26 |
Est. completion date | July 2012 |
Est. primary completion date | July 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - At least one severe gastroparetic symptom or two moderate gastroparetic symptoms (see assessment of gastroparetic symptoms); - Abnormal gastric emptying defined as more than 10% of gastric retention at 4 hrs after a standard solid meal (see below) during the past 3 months; - Males and females between ages 18-65 yrs; - Subjects with high probability for compliance and completion of the study. - Upper endoscopy or upper GI within last 2 years showing no evidence of gastric bezoar, stricture, or peptic ulcer. - Diabetes. Exclusion Criteria: 1) History of gastric bezoar or diverticulitis. 2) Severe daily abdominal pain requiring medications for relief. 3) Severe weight loss, greater than 10 lbs over the preceding 2 months. 4) Uncontrolled diabetes with a hemoglobin A1C greater than 10. 5) Excessively delayed gastric emptying time: more than 90% of a standard meal retained after 2 hours. 6) Previous gastro-esophageal surgery including vagotomy, fundoplication, gastric bypass, ulcer surgery. 7) Prior GI surgery except for uncomplicated appendectomy and laparoscopic cholecystectomy; 8) Surgery within the past 3 months. 9) Female of childbearing age who is not practicing birth control and/or is pregnant or lactating. (Confirm with urine pregnancy test). 10) Those who have been treated with acupuncture or those who are familiar with acupuncture points. 11). Allergic to Ensure, strawberry jam and eggs. |
Country | Name | City | State |
---|---|---|---|
United States | Texas tech university health science center | El Paso | Texas |
United States | University of Mississippi | Jackson | Mississippi |
Lead Sponsor | Collaborator |
---|---|
Transtimulation Research, Inc | National Center for Complementary and Integrative Health (NCCIH), Texas Tech University Health Sciences Center, University of Mississippi Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | gastroparesis symptoms | Gastroparetic symptom questionnaire will use the previously validated gastroparesis cardinal symptom index (GCSI), including 9 symptoms: nausea (feeling sick to your stomach as if you were going to vomit or throw up), retching (heaving as if to vomit, but nothing comes up), vomiting, stomach fullness, not able to finish a normal sized meal, feeling excessively full after meals, loss of appetite, bloating (feeling like you need to loose your clothes) and stomach or belly visibly larger. Each symptom will be graded from 0 to 5 (none, very mild, mild, moderate, severe and very severe). | 4 weeks | |
Secondary | Gastric emptying | Gastric emptying of a solid meal. | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01557296 -
Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis
|
Phase 2 | |
Withdrawn |
NCT03376399 -
Potential Benefits of Sleeve Gastrectomy Surgery on Diabetic Gastroparesis Symptoms
|
||
Not yet recruiting |
NCT02264587 -
Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis
|
Phase 4 | |
Completed |
NCT02289846 -
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
|
Phase 2 | |
Completed |
NCT03544229 -
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
|
Phase 2 | |
Recruiting |
NCT04706832 -
Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study
|
N/A | |
Not yet recruiting |
NCT05584462 -
Gastroparesis in type2 Diabetic Patient
|
||
Enrolling by invitation |
NCT05812339 -
Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls
|
||
Completed |
NCT02732821 -
G-POEM for Treatment of Refractory Gastroparesis
|
||
Completed |
NCT01030341 -
Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis
|
N/A | |
Recruiting |
NCT05832151 -
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
|
Phase 2 | |
Completed |
NCT02025725 -
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
|
Phase 3 | |
Completed |
NCT01916460 -
Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients
|
N/A | |
Terminated |
NCT00874133 -
The Effect of Acupuncture on Symptoms, Gastric Emptying Rate and Glucose Control in Patients With Diabetic Gastroparesis
|
N/A | |
Completed |
NCT01126034 -
Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention
|
N/A | |
Recruiting |
NCT05273788 -
Thoracic Neuromodulation for Diabetic Gastroparesis
|
N/A | |
Suspended |
NCT00470795 -
Acupuncture for Diabetic Gastroparesis
|
Phase 3 | |
Completed |
NCT00139893 -
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
|
N/A | |
Recruiting |
NCT04254549 -
Rifaximin in Patients With Diabetic Gastroparesis
|
Phase 2 | |
Not yet recruiting |
NCT04661215 -
Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms
|